Andrographolide ameliorates hepatic steatosis by suppressing FATP2-mediated fatty acid uptake in mice with nonalcoholic fatty liver disease
暂无分享,去创建一个
Yawen Wu | Honglian Wang | Hong-min Zhang | Ran Xiong | Liyuan Ran | Chen Chen | Li Wang | Li-Juan Wu | Yonglin Li | S. Lei | Xue Wang | Chun-Mei Zheng | Yi-Wen Gan | Yao Ming | Xiaoxing Lao | Chang-Ying Zhao
[1] Qiang Xu,et al. Advances in ameliorating inflammatory diseases and cancers by andrographolide: Pharmacokinetics, pharmacodynamics, and perspective , 2021, Medicinal research reviews.
[2] H. El‐Serag,et al. Global epidemiology of NAFLD-related HCC: trends, predictions, risk factors and prevention , 2020, Nature Reviews Gastroenterology & Hepatology.
[3] G. Kumar,et al. Andrographolide: Chemical modification and its effect on biological activities. , 2019, Bioorganic chemistry.
[4] T. Kellogg,et al. Evolution of NAFLD and Its Management. , 2019, Nutrition in clinical practice : official publication of the American Society for Parenteral and Enteral Nutrition.
[5] Jian Sun,et al. Inhibition of AIM2 inflammasome-mediated pyroptosis by Andrographolide contributes to amelioration of radiation-induced lung inflammation and fibrosis , 2019, Cell Death & Disease.
[6] J. Lykkesfeldt,et al. Molecular mechanisms of hepatic lipid accumulation in non-alcoholic fatty liver disease , 2018, Cellular and Molecular Life Sciences.
[7] N. Al-Dhabi,et al. Effect of two andrographolide derivatives on cellular and rodent models of non-alcoholic fatty liver disease. , 2017, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.
[8] K. Kuo,et al. Pioglitazone Enhances Cytosolic Lipolysis, β-oxidation and Autophagy to Ameliorate Hepatic Steatosis , 2017, Scientific Reports.
[9] A. Wree,et al. Andrographolide Ameliorates Inflammation and Fibrogenesis and Attenuates Inflammasome Activation in Experimental Non-Alcoholic Steatohepatitis , 2017, Scientific Reports.
[10] Qiang Xu,et al. Andrographolide sulfonate ameliorates lipopolysaccharide-induced acute lung injury in mice by down-regulating MAPK and NF-κB pathways , 2016, Acta pharmaceutica Sinica. B.
[11] J. Fitzgerald,et al. Gout Guidelines: The Good, the Bad, and the Future , 2014 .
[12] Li Yang,et al. Andrographolide Prevents High-Fat Diet–Induced Obesity in C57BL/6 Mice by Suppressing the Sterol Regulatory Element-Binding Protein Pathway , 2014, The Journal of Pharmacology and Experimental Therapeutics.
[13] S. Koo,et al. Nonalcoholic fatty liver disease: molecular mechanisms for the hepatic steatosis , 2013, Clinical and molecular hepatology.
[14] M. Mandal,et al. Evaluation of anti-bacterial and anti-oxidant potential of andrographolide and echiodinin isolated from callus culture of Andrographis paniculata Nees. , 2013, Asian Pacific journal of tropical biomedicine.
[15] J. M. Suh,et al. PPARγ signaling and metabolism: the good, the bad and the future , 2013, Nature Medicine.
[16] D. Xia,et al. Andrographolide sensitizes cisplatin-induced apoptosis via suppression of autophagosome-lysosome fusion in human cancer cells , 2012, Autophagy.
[17] L. Gordon,et al. Mitochondrial-Mediated Apoptosis in Lymphoma Cells by the Diterpenoid Lactone Andrographolide, the Active Component of Andrographis paniculata , 2010, Clinical Cancer Research.
[18] M. Kay,et al. FATP2 is a hepatic fatty acid transporter and peroxisomal very long-chain acyl-CoA synthetase. , 2010, American journal of physiology. Endocrinology and metabolism.
[19] Theresa A. Storm,et al. Silencing of Hepatic Fatty Acid Transporter Protein 5 in Vivo Reverses Diet-induced Non-alcoholic Fatty Liver Disease and Improves Hyperglycemia* , 2008, Journal of Biological Chemistry.
[20] R. Gimeno,et al. Targeted deletion of FATP5 reveals multiple functions in liver metabolism: alterations in hepatic lipid homeostasis. , 2006, Gastroenterology.
[21] L. Standish,et al. A phase I trial of andrographolide in HIV positive patients and normal volunteers , 2000, Phytotherapy research : PTR.
[22] Anupam Sharma,et al. Hepatoprotective activity of andrographolide from Andrographis paniculata against carbontetrachloride. , 1990, The Indian journal of medical research.
[23] B. Staels,et al. PPARs in obesity-induced T2DM, dyslipidaemia and NAFLD , 2017, Nature Reviews Endocrinology.